XERIS BIOPHARMA HOLDINGS, INC. (XERS) Net margin 2020–2025
XERIS BIOPHARMA HOLDINGS, INC. (XERS) net profit margin by fiscal year — reported net income divided by reported revenue.
0.2%FY2025 · since FY2020: -452.2% → 0.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 0.2% | +27.2 pp |
| FY2024 | -27.0% | +11.0 pp |
| FY2023 | -38.0% | +47.9 pp |
| FY2022 | -85.9% | +161.6 pp |
| FY2021 | -247.5% | +204.7 pp |
| FY2020 | -452.2% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More XERS financial trends
XERS RevenueXERS Net incomeXERS Gross profitXERS Gross marginXERS Operating incomeXERS Operating marginXERS Operating cash flowXERS Free cash flowXERS Capital expendituresXERS Return on equityXERS Stock buybacksXERS Dividends paidXERS Total assetsXERS Total liabilitiesXERS Shareholders’ equityXERS overview →